By NEIL UNMACK
With the stake in Acerta, the British drug company’s acquisitions this quarter total more than $7 billion. The deal-making reflects pipeline challenges and price pressure.
Published: December 18, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1Rrqt5G
from WordPress http://ift.tt/1Qvy4A3
via Hadi Aboukhater
No comments:
Post a Comment